VeriStrat is a non-invasive test that helps physicians guide therapy for 2nd and 3rd line NSCLC patients.
VeriStrat has been clinically validated as a pre-treatment serum test that predicts clinical benefit in patients with advanced non-small cell lung cancer treated with erlotinib.1 For data from clinical trials, click on the links below.
References
1 Carbone D, 2nd European Lung Cancer Conference, April 2010.
